Small molecule-induced polymerization triggers degradation of BCL6

Effective and sustained inhibition of non-enzymatic oncogenic driver proteins represents a major pharmacologic challenge. The clinical success of thalidomide analogs demonstrates the therapeutic efficacy of drug-induced degradation of transcription factors and other cancer targets(1–3), but a signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Słabicki, Mikołaj, Yoon, Hojong, Koeppel, Jonas, Nitsch, Lena, Roy Burman, Shourya S., Di Genua, Cristina, Donovan, Katherine A., Sperling, Adam S., Hunkeler, Moritz, Tsai, Jonathan M., Sharma, Rohan, Guirguis, Andrew, Zou, Charles, Chudasama, Priya, Gasser, Jessica A., Miller, Peter G., Scholl, Claudia, Fröhling, Stefan, Nowak, Radosław P., Fischer, Eric S., Ebert, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816212/
https://www.ncbi.nlm.nih.gov/pubmed/33208943
http://dx.doi.org/10.1038/s41586-020-2925-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816212/
https://www.ncbi.nlm.nih.gov/pubmed/33208943
http://dx.doi.org/10.1038/s41586-020-2925-1

Ejemplares similares